Pipeline
Conditionally active precision oncology therapeutics
Our pipeline directly validates the capabilities of our computational platform and is guided by two core objectives.
First, we use our platform to reduce off-tumor target engagement and develop antibody-drug conjugates (ADCs) for tumor antigens that have historically been difficult to drug due to expression in healthy tissues. This allows us to pursue cancers where treatment options remain limited and survival rates are still unacceptably low.
Second, by improving specificity, we aim to enhance the bioavailability and tolerability of our therapeutics, supporting more effective treatments for patients who may be unable to tolerate existing therapies or are forced to discontinue treatment due to complications.
Through this work, we aim to advance clinically meaningful, broadly applicable, and more inclusive cancer therapies – offering renewed hope to patients and their families.
Therapeutic Programs
9B02: Anti-PD-L1
Monoclonal ADC9B02 is a conditional, tumor-selective anti-PD-L1 ADC designed to address key limitations of current PD-1/PD-L1 therapies. By preferentially binding PD-L1 within the tumor microenvironment, 9B02 is designed to improve tumor selectivity and patient tolerability.
It enables direct elimination of both PD-L1-positive tumor cells and immunosuppressive tumor-resident immune cells, offering a differentiated mechanism beyond checkpoint inhibition and potential benefit in patients with compromised immune function following chemotherapy or radiation.
Its conditional binding profile is also being leveraged in next-generation bispecifics to improve the safety of challenging tumor targets through avidity-driven tumor-selective binding. 9Bio is open to collaborations that advance differentiated bi- or multispecific therapeutics using our conditional anti-PD-L1 antibodies.
9B05: Undisclosed target
Bispecific ADC9B05 is a bispecific ADC for the treatment of patients with advanced metastatic cancers. It combines a clinically validated tumor antigen associated with cancer stemness, chemotherapy resistance, and metastasis, supported by prior Phase 1 evidence of anti-tumor activity, with a second novel tumor antigen associated with metastatic progression in colorectal, gastric, and breast cancers.
The program is currently in lead characterization and optimization in the bispecific format and is being advanced for late-stage, particularly metastatic breast, colorectal, gastric, and liver cancers.
9B06: Undisclosed target
Bispecific ADC9B06 is a next-generation bispecific ADC that combines 9Bio’s conditional, tumor-selective anti-PD-L1 ADC platform with a complementary tumor-associated antigen linked to aggressive and metastatic disease.
By pairing conditional PD-L1 targeting with a second tumor-localizing arm, 9B06 is designed to improve tumor selectivity through avidity-driven binding while enabling direct cytotoxic activity against both PD-L1-positive tumor cells and immunosuppressive cells within the tumor microenvironment.
This approach is intended to extend the potential of 9B02 beyond single-target PD-L1 biology and support treatment of advanced tumors where immune suppression, metastatic progression, and heterogeneous target expression limit current therapeutic options.